Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
about
Update on treatment of light chain amyloidosisRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisBiomarkers in cardiology--part 1--in heart failure and specific cardiomyopathiesN-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.Future directions in the clinical management of amyloid light-chain amyloidosis.Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Current applications of biomarkers in cardiomyopathies.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Systemic amyloidosis: novel therapies and role of biomarkers.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac responseHigh-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.New concepts in the treatment and diagnosis of amyloidosis.Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis.[Treatment of systemic AL amyloidosis: about 25 cases].Novel Therapies in Light Chain Amyloidosis.Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function
P2860
Q26829735-A2D16A48-C416-42D8-A78B-018E2AB06379Q28069975-F628C269-5B25-4FA7-8CB1-C42A7A3CB260Q34914470-956B1275-AB30-4163-9388-F9D44E69226CQ37456396-A61C4C89-A9EF-4CB2-92D9-D5775C85980FQ38172998-99E81223-C9BD-42DB-A94C-524FD14F2672Q38244397-7EBFBAE0-A245-49B7-AC2D-7A6AB82733F5Q38536678-165D516D-502E-4831-B2A5-19A1D8E35B70Q38614967-4B94F84C-7F07-4FF6-8FFD-3E309B749584Q38779623-A868200D-A6D6-4BC9-AA0E-71E8DE32E1B0Q38829923-8152AB30-4B71-46A6-89B4-4C00A46F58E2Q39272596-B6432967-E958-4D8C-AA26-3E9EA07F1A47Q41021929-CFD90D89-F455-4A93-B635-EB9056DADD15Q41714209-6D4C1E94-2815-4554-92E4-667D4B92951AQ43936667-F12F30EF-35F9-4C90-A69C-DB4B32B87E80Q44538488-A4126BFF-2A6D-4357-A7D9-B73690600FE1Q47561519-2EA3FFD8-10D4-4DD0-9CCB-BA29E9B392EEQ47952949-431856FB-14A1-4984-A6A3-AFB9850E3904Q54941597-F81792FE-4527-476D-9D65-9DE803FB64E5Q55127439-48BCF22A-EF13-45B1-A879-94E4F2A3E53CQ58804421-33F186A7-61BA-4068-B761-040196E61CC4
P2860
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@en
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@nl
type
label
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@en
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@nl
prefLabel
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@en
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@nl
P2093
P2860
P50
P356
P1476
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
@en
P2093
Andrea Foli
Francesca Lavatelli
Paola Russo
Remigio Moratti
Riccardo Albertini
P2860
P304
P356
10.1002/AJH.23141
P577
2012-03-03T00:00:00Z